Subcutaneous ofatumumab in recurrent focal segmental glomerulosclerosis after kidney transplantation
We propose a combination treatment of subcutaneous ofatumumab and intensive plasmapheresis, with CD19 and CD20 levels monitored regularly, might be safe and effective in rFSGS in KT patients.
Authors
- Shirley Pollack (ORCID: https://orcid.org/0000-0002-9129-3165)
- Moran Plonsky
- Rami Tibi
- Daniella Magen (ORCID: https://orcid.org/0000-0001-8825-5259)
- Irina Libinson-Zebegret
- Renata Yakobov
Institutions
- Technion – Israel Institute of Technology (IL)
- Rambam Health Care Campus (IL)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1093/ckj/sfaf083
- Citations
- 2
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.86